Recruiting NCT06554509
Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: SHR-1819 Injection, SHR-1819 Injection Placebo.
- Who it may be relevant to
- Registry conditions: Prurigo Nodularis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis
Overview
This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with Prurigo Nodularis.
Interventions
- Drug SHR-1819 Injection
SHR-1819 injection. - Drug SHR-1819 Injection Placebo
SHR-1819 injection placebo.
Primary outcome measures
- Phase II: Proportion of subjects with a ≥ 4-point reduction from baseline in the weekly mean of the Most Intense Pruritus Numeric Rating Scale (WI-NRS) at Week 16 [Time frame: Up to 16 weeks.]
- Phase III: Proportion of subjects with a ≥ 4-point reduction from baseline in the weekly mean of the Most Intense Pruritus Numeric Rating Scale (WI-NRS) at Week 24 [Time frame: Up to 24 weeks.]
Secondary outcome measures (9)
- Phase II: Weekly mean change from baseline and percentage change in weeks 2, 4, 8, 12, and 16 of WI-NRS [Time frame: Up to 16 weeks.]
- Phase II: Proportion of subjects with IGA CNPG-S score of 0/1 at weeks 4, 8, 12 and 16 [Time frame: Up to 16 weeks.]
- Phase II: Change from baseline in Dermatology Life Quality Index (DLQI) score at weeks 4, 8, 12, 16 [Time frame: Up to 16 weeks.]
- Phase III: Proportion of subjects with an IGA CNPG-S score of 0/1 at Week 24 [Time frame: Up to 24 weeks.]
- Phase III: Proportion of subjects with IGA CNPG-S score of 0/1 at every study visit [Time frame: Up to 52 weeks.]
- Phase III: Change from baseline in Dermatology Life Quality Index (DLQI) score at every study visit [Time frame: Up to 52 weeks.]
- Phase II/III: The concentration of SHR-1819 in serum (AUC) [Time frame: From the beginning of administration to the 24/60th week.]
- Phase II/III: Changes in the level of IgE in the serum [Time frame: From the beginning of administration to the 24/60th week.]
- Phase II/III: Immunogenic endpoint - evaluate the incidence of ADA positivity for SHR-1819 [Time frame: From the beginning of administration to the 24/60th week.]
Eligibility criteria
Inclusion criteria
- Subjects voluntarily sign informed consent forms prior to the commencement of any proceedings related to the study, are able to communicate smoothly with the investigator, understand and are willing to complete the study in strict compliance with the requirements of this clinical research protocol.
- The age was ≥18 at the time of signing the informed consent and gender is unlimited.
- Has prurigo nodularis at screening.
Exclusion criteria
- Pregnant or lactating women.
- Screening for people with a history of heavy alcohol consumption or substance abuse in the 6 months prior to screening.
- Has an active skin disease or skin complications due to other diseases that may affect the evaluation of PN.
- PN secondary to medical conditions such as neurological or psychiatric disorders.
- Diagnosis of moderate to severe AD during the screening/lead-in period or prior to randomization.
- History of clinically significant diseases (e.g., circulatory system abnormalities, endocrine system abnormalities, neurological disorders, hematologic disorders, immune system disorders, psychiatric disorders, and metabolic instability) that the researcher believes that participation in the study poses a risk to the safety of the subject or that the disease/illness worsens during the study period will affect the effectiveness or safety analysis.
- Phase II: Treated with biologics targeting IL-4Rα, or participated in previous clinical studies of biologics targeting IL-4Rα, including SHR-1819 injection. Phase III: Subjects who have previously received anti-IL-4Rα biologics for any indication including atopic dermatitis (AD), asthma, sinusitis, etc., and were judged by the investigator to have an inadequate response or intolerance (e.g., experienced drug-related adverse reactions requiring treatment discontinuation) must be excluded even if the washout requirement is met.
- Subjects with malignancy prior to screening (except for squamous cell carcinoma of the skin, basal cell carcinoma, or carcinoma in situ of the cervix that are completely resected and have no evidence of recurrence).
- Major surgeries are planned for the duration of the study.
- Other conditions that, in the opinion of the investigator, are not suitable for participation in this study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- Peking University People's Hospital — Beijing
Identifiers
NCT: NCT06554509 · SHR-1819-302